Age-related loss of Y chromosome is associated with mortality after ST-segment elevation myocardial infarction Authors: Nan Li, Jiannan Li, Yu Tan, Runzhen Chen, Xiaoxiao Zhao, Peng Zhou, Chen Liu, Jinying Zhou, Yi Chen, Shaodi Yan, Hanjun Zhao, Li Song, Hongbing Yan Published: 2026 ABSTRACT BackgroundWhile loss of Y chromosome (LOY), a common somatic alteration with aging, has been associated with cardiovascular diseases, its specific impact on ST-segment elevation myocardial infarction (STEMI) remains underexplored.MethodsThis study enrolled 928 males undergoing primary percutaneous coronary intervention for STEMI to investigate the impact of LOY in blood cells on all-cause mortality. LOY was measured in males using droplet digital polymerase chain reaction technique. The primary outcome was all-cause mortality.ResultsDuring a median of 3.99-year follow-up, 93 males (10.0%) died. Of these, 39 (4.2%) died within 1 year, 56 (6.0%) within 2 years, and 67 (7.2%) within 3 years. Compared to males with LOY < 18% (the 90th percentile), those with LOY ≥ 18% had an increased mortality after multivariable adjustment including age, with adjusted hazard ratios (HRs) of 2.45 (95% confidence interval [CI]: 1.16–5.15; P = 0.018), 2.11 (95% CI: 1.11–4.01; P = 0.024), and 1.88 (95% CI: 1.02–3.45; P = 0.043) at 1-, 2-, and 3-year follow-up, respectively. Among males without prior MI, those with LOY ≥ 18% have higher mortality than those with LOY < 18% (adjusted HR 1.93; 95% CI: 1.01–3.67; P = 0.045), whereas no significant association is observed in males with prior MI.ConclusionsLOY ( ≥ 18%) is associated with an increased 1-, 2-, and 3-year mortality in male STEMI patients and may serve as a potential biomarker for risk stratification. Introduction ST-segment elevation myocardial infarction (STEMI) is a typical and critical representative of cardiovascular diseases. Despite substantial progress in reperfusion and pharmacological therapies for myocardial infarction (MI) over the past few decades, some patients experience recurrent cardiovascular events and even death under the standard treatment1–3. Accordingly, it is crucial to further understand the pathophysiology involved in prognosis and establish more precise methods to identify high-risk patients in clinical practice. Mosaic loss of Y chromosome (LOY), a common subtype of somatic mosaicism, is characterized by some cells losing the entire Y chromosome and rises with age, with more than 10% of blood cells exhibiting LOY in 10–40% of males aged 70 years and above4–7. Previous epidemiological studies demonstrate that men with LOY have a shorter life expectancy and are more prone to age-related diseases, such as cancer and cardiovascular diseases8–12. Experimental study has also shown that the LOY in macrophages induces cardiac fibrosis, leading to cardiac dysfunction and increased mortality13. Given that males constitute approximately 80% of STEMI patients14,15, investigating the relationship between LOY and prognosis in male STEMI patients may provide evidence for risk assessment. Therefore, we explore the impact of LOY in blood cells on all-cause mortality in male patients with STEMI who underwent primary percutaneous coronary intervention (PCI) in the present study. Our results demonstrate that males with a high level of LOY have an increased short- to mid-term mortality risk (1–3 years), independent of age and traditional cardiovascular risk factors. The association is more noticeable among males without a prior MI. These findings suggest that LOY may serve as a novel genomic biomarker for risk stratification and prognosis in male STEMI patients. Methods Study population Patients who underwent primary PCI for STEMI at Fuwai Hospital (Beijing, China) between March 2017 and January 2020 were prospectively enrolled. STEMI was diagnosed according to current guidelines16–18, including elevated troponin I levels, ST-segment elevation in the electrocardiogram, and clinical evidence of ischemia. The exclusion criteria for male patients were as follows: (1) missing LOY measurement, and (2) the blood sample for the LOY measure was unqualified. In addition, contemporary female patients were included to provide a clinical reference group representing a population without a Y chromosome. Sex (male or female) was based on medical records at hospital admission. The flowchart of this study is shown in Fig. S1. This study was approved by the Ethics Committee of Fuwai Hospital (No. 2017-866) under the Declaration of Helsinki. All patients provided signed informed consent. Data collection Baseline information, encompassing demographics, medical history, signs and symptoms, laboratory findings, echocardiographic evaluations, and discharge medications, was gathered by trained healthcare staff with rigorous quality-control processes. Follow-up information was obtained through telephone interviews and outpatient visits by trained cardiologists at scheduled intervals, including 1, 6, and 12 months after discharge, followed by annual assessments. Follow-up time was initiated on the day of the PCI. Endpoint definition and adjudication All-cause mortality was the primary endpoint for this study. A clinical endpoint committee, comprising five clinicians with cardiology backgrounds who were not involved in this study, was responsible for verifying all reported endpoint events. Endpoint events were determined based on diagnostic (death) certificates, medical consultation records, laboratory results, imaging test results, and telephone recordings. Causes of death were classified according to the International Classification of Diseases (ICD-10) as cardiovascular, non- cardiovascular, or undetermined. All deaths were included in the primary endpoint of all-cause mortality irrespective of etiology, to avoid misclassification bias and to capture the overall prognostic impact of LOY. No deaths were excluded after adjudication, and the distribution of causes is presented in Table S1. LOY measurement LOY was measured using the droplet digital PCR technique (QX200 Droplet Digital PCR System, Bio-Rad Laboratories, Inc., CA, USA), which has been validated in previous studies5,19,20. DNA was extracted from arterial blood samples before heparinization and PCI procedures. The relative numbers of X and Y chromosomes in the DNA samples were quantified using the TaqMan-based approach. DNA samples were mixed in a PCR supermix for probes without dUTP (Bio-Rad, article number: 186–3024) together with TaqMan primers and probes (Thermo Fisher Scientific, MA, USA, article number C_990000001_10). According to the manufacturer’s instructions, droplets were created and subjected to PCR amplification under specific conditions. Subsequently, the fluorescence intensities for FAM (targeting AMELY) and VIC (targeting AMELX) were measured in each droplet using a droplet reader. The ratio of AMELY to AMELX was determined based on absolute concentrations utilizing Bio-Rad’s QuantaSoft software (version 1.7.4.0917). The extent of LOY was calculated as 1 − AMELY/AMELX. Each DNA sample underwent duplicate runs, and the samples were reanalyzed if the ratio exceeded 1.1. Statistical and reproducibility Continuous variables were assessed for normality using the Shapiro–Wilk test and for variance homogeneity using Levene’s test. Variables with approximately normal distributions and equal variances were summarized as mean ± standard deviation, and Pearson’s correlation was applied for correlation analyses. Non-normally distributed variables or those with unequal variances were summarized as median (interquartile range, IQR) and analyzed using Spearman’s correlation. Categorical variables were summarized as counts and percentages and compared using the χ² test or Fisher’s exact test as appropriate. Missing data were handled using a complete-case approach. First, to determine the cutoff value of LOY in its impact on all-cause mortality, male patients were classified into high and low LOY groups based on the 97th percentile (top 3%), 95th percentile (top 5%), 90th percentile (top 10%), and 80th percentile (top 20%) of LOY. Then, univariable Cox proportional risk regression was conducted to compare the risk of all-cause mortality in high and low LOY groups. Second, according to the above cutoff value, mortality in high and low LOY groups was compared by Kaplan–Meier curves, the log-rank test, and Cox proportional risk regression, as well as adjusted survival curves generated based on multivariable Cox models over the entire follow-up period and at 1-, 2-, and 3-year intervals. The relationship between the hazard ratio (HR) for all-cause mortality and LOY as a continuous variable was also evaluated using restricted cubic spline (RCS) regression analysis. Multivariable Cox regression was adjusted for traditional cardiovascular risk factors, including age, body mass index, current smoking, hypertension, dyslipidemia, diabetes mellitus, and peripheral artery disease21, with Model 1 adjusting for traditional cardiovascular risk factors except for age and Model 2 adjusting for all confounding factors. Besides, to test the robustness of our findings, we conducted two extended models. Model 3 was additionally adjusted for multiple vessels disease (MVD) and prior MI, and Model 4 was additionally adjusted for MVD and prior PCI. Finally, subgroup analyses were conducted according to baseline characteristics (details shown in Supplementary Materials). Subgroup effects were assessed by testing the interaction between the LOY group and subgroup variables in the univariable Cox model. P values for interaction were reported, subgroup-specific estimates were considered exploratory, and no formal adjustment for multiple testing was made. Additionally, subgroup analysis by 10-year age intervals was performed due to the positive association between LOY and age as reported. For each subgroup, high and low LOY groups were classified using the value of the top 10% of the group as the cutoff value. Meanwhile, contemporary females with STEMI were also included in survival analysis as a contextual, sex-based reference group. Given that females (constitutional XX karyotype) are not biologically comparable to males with mosaic LOY, analyses involving female participants were predefined as descriptive and exploratory, and not intended to serve as mechanistic or biologically equivalent comparisons. Statistical analyses were performed using SPSS software (version 26.0; IBM Corp., Armonk, New York, USA) and R. All statistical tests were two-sided, and statistical significance was set at P < 0.05. Results LOY distribution and the association with baseline characteristics The final analysis included 928 male patients. The median LOY in blood cells was 4.1% (IQR, 0–9.7%, Fig. S2A). The 97%, 95%, 90%, and 80% percentiles of LOY were 33%, 25%, 18%, and 12%, respectively. The extent of LOY increased gradually with age, reaching a median LOY of 8.7% (IQR, 2.8–19.9%) in patients over 80 years (Fig. S2B, C). Regarding the association of LOY with baseline variables (Table S2), there were positive correlations between LOY and age (R = 0.22, P < 0.001), and the baseline (R = 0.08, P = 0.022) and peak (R = 0.08, P = 0.022) values of N-terminal pro B-type natriuretic peptide (NT-proBNP). Conversely, there were negative correlations between LOY and levels of left ventricular ejection fraction (LVEF) (R = −0.07, P = 0.032), total cholesterol (R = −0.10, P = 0.003), and low-density lipoprotein cholesterol (R = −0.09, P = 0.008). The cutoff value of LOY To investigate the association between LOY and all-cause mortality, patients were categorized into high and low LOY groups based on the 97% (top 3%), 95% (top 5%), 90% (top 10%), and 80% (top 20%) LOY percentiles. Using different cutoff values, the number of patients in the high and low LOY groups were as follows: 28 vs. 900 (top 3%), 47 vs. 881 (top 5%), 92 vs. 836 (top 10%), and 177 vs. 751 (top 20%). The risk of all-cause mortality between the high and low LOY groups using the above cutoff values were compared in Fig. S3. Notably, patients with high LOY had a significantly elevated risk of all-cause mortality compared to those with low LOY at the 18% cutoff (top 10%) (HR 2.00, 95% confidence interval [CI]: 1.15–3.48; P = 0.014). Baseline characteristics of the low and high LOY groups Given the between-group differences when grouped at 18% (top 10%), further analysis of the baseline characteristics of these patients was conducted (Tables 1 and S3). Compared to males with LOY < 18%, those with LOY ≥ 18% were older, had poorer cardiac function (lower LVEF, higher Killip class, and elevated NT-proBNP levels), and higher proportions of MVD, previous MI and PCI. Besides, female patients with STEMI during the same period were also compared. Differences in baseline characteristics of the three groups were summarized in Table S4. In comparison, female patients were the oldest, had the highest proportion of hypertension, and had the highest baseline troponin I and NT-proBNP levels, as well as total cholesterol, low-density lipoprotein cholesterol, and lipoprotein (a) levels; males with LOY ≥ 18% had a higher proportion of prior MI and PCI than did females.Table 1Baseline characteristics according to the dichotomized loss of the Y chromosome ratioTotal(n = 928)LOY < 18%(n = 836)LOY ≥ 18%(n = 92)P-valueAge (years)58.8 (55.0, 66.0)57.9 (50.0, 65.0)65.0 (56.0, 73.5)<0.001≥75years84 (9.1)61 (7.3)23 (25.0)<0.001BMI (kg/m2)25.9 (23.4, 28.0)26.0 (23.4, 28.0)25.4 (23.4, 28.2)0.775Current smoker784 (84.5)709 (84.8)75 (81.5)0.409Hypertension564 (60.8)506 (60.5)58 (63.0)0.639Dyslipidemia838 (90.3)753 (90.1)85 (92.4)0.476Diabetes mellitus291 (31.4)259 (31.0)32 (34.8)0.456Previous stroke123 (13.3)107 (12.8)16 (17.4)0.218CKD55 (5.9)49 (5.9)6 (6.5)0.799PAD45 (4.8)38 (4.5)7 (7.6)0.199Previous MI156 (16.8)131 (15.7)25 (27.2)0.005Previous PCI155 (16.7)125 (15)30 (32.6)<0.001Anterior MI432 (46.6)383 (45.8)49 (53.3)0.174MVD685 (73.8)608 (72.7)77 (83.7)0.023Continuous variables are presented as medians (25–75th percentiles), and categorical variables are reported as counts (%).BMI body mass index, CKD chronic kidney disease, DM diabetes mellitus, LVEF left ventricular ejection fraction, MI myocardial infarction, MVD multiple vessels disease, PAD peripheral artery disease, PCI percutaneous coronary intervention. Table 1Baseline characteristics according to the dichotomized loss of the Y chromosome ratioTotal(n = 928)LOY < 18%(n = 836)LOY ≥ 18%(n = 92)P-valueAge (years)58.8 (55.0, 66.0)57.9 (50.0, 65.0)65.0 (56.0, 73.5)<0.001≥75years84 (9.1)61 (7.3)23 (25.0)<0.001BMI (kg/m2)25.9 (23.4, 28.0)26.0 (23.4, 28.0)25.4 (23.4, 28.2)0.775Current smoker784 (84.5)709 (84.8)75 (81.5)0.409Hypertension564 (60.8)506 (60.5)58 (63.0)0.639Dyslipidemia838 (90.3)753 (90.1)85 (92.4)0.476Diabetes mellitus291 (31.4)259 (31.0)32 (34.8)0.456Previous stroke123 (13.3)107 (12.8)16 (17.4)0.218CKD55 (5.9)49 (5.9)6 (6.5)0.799PAD45 (4.8)38 (4.5)7 (7.6)0.199Previous MI156 (16.8)131 (15.7)25 (27.2)0.005Previous PCI155 (16.7)125 (15)30 (32.6)<0.001Anterior MI432 (46.6)383 (45.8)49 (53.3)0.174MVD685 (73.8)608 (72.7)77 (83.7)0.023Continuous variables are presented as medians (25–75th percentiles), and categorical variables are reported as counts (%).BMI body mass index, CKD chronic kidney disease, DM diabetes mellitus, LVEF left ventricular ejection fraction, MI myocardial infarction, MVD multiple vessels disease, PAD peripheral artery disease, PCI percutaneous coronary intervention. Baseline characteristics according to the dichotomized loss of the Y chromosome ratio Continuous variables are presented as medians (25–75th percentiles), and categorical variables are reported as counts (%). BMI body mass index, CKD chronic kidney disease, DM diabetes mellitus, LVEF left ventricular ejection fraction, MI myocardial infarction, MVD multiple vessels disease, PAD peripheral artery disease, PCI percutaneous coronary intervention. The association between LOY and all-cause mortality During a median follow-up of 3.99 (IQR, 3.15–4.97) years, 93 male patients (10.0%) died. Of these, 39 (4.2%) died within 1 year, 56 (6.0%) within 2 years, and 67 (7.2%) within 3 years. A total of 52 (55.9%) deaths were attributed to cardiovascular causes, 36 (38.7%) to non-cardiovascular causes, and 5 (5.4%) were of undetermined causes (Table S1). Regarding the relationship between LOY and all-cause mortality over the entire follow-up period, the unadjusted Kaplan–Meier curves showed that the rate of all-cause mortality was higher in males with LOY ≥ 18% than in those with LOY < 18% (Plog-rank = 0.012, Fig. S4A). Univariable Cox regression indicated that patients with LOY ≥ 18% were at a higher risk of all-cause mortality (HR 2.00, 95% CI: 1.15–3.48; P = 0.014, Table 2). This difference is still significant after taking into account traditional cardiovascular risk factors excluding age (Model 1: HR 2.01, 95% CI: 1.15–3.50; P = 0.014, Table 2), whereas it disappeared after adjusting for confounders including age (Model 2: HR 1.30, 95% CI: 0.74–2.29; P = 0.368, Table 2 and Fig. 1A). RCS curve indicated that the risk of all-cause mortality increased with increasing LOY, whereas it did not meet statistical significance (Pfor linearity = 0.235, Pfor nonlinearity = 0.435, Fig. S5A). To assess the robustness of the association between LOY and all-cause mortality, further subgroup analyses were conducted according to the baseline characteristics (Fig. S6). The results were consistent for all other subgroups except for a previous history of MI (all Pfor interaction > 0.05).Fig. 1Adjusted survival curves derived from multivariable Cox models for the cumulative survival rate between groups by dichotomized loss of Y chromosome ratio.A The entire follow-up period; B 1 year; C 2 years; D 3 years. The cutoff value for LOY was 18% (top 10% percentile). Follow-up time was initiated on the day of the percutaneous coronary intervention. The multivariable Cox model was adjusted for age, body mass index, current smoker, hypertension, dyslipidemia, diabetes mellitus, and peripheral artery disease (Model 2). LOY loss of Y chromosome.Table 2Association between all-cause death and dichotomized loss of Y chromosome ratioFollow-up timeGroupEvent(n.%)crude.HR (95% CI)P-valueModel 1HR (95% CI)P-valueModel 2HR (95% CI)P-valueAllLOY < 18%78 (9.3)1 (Ref)1 (Ref)1 (Ref)LOY ≥ 18%15 (16.3)2.00 (1.15–3.48)0.0142.01 (1.15–3.50)0.0141.30 (0.74–2.29)0.3681 yearLOY < 18%29 (3.5)1 (Ref)1 (Ref)1 (Ref)LOY ≥ 18%10 (10.9)3.24 (1.58–6.64)0.0013.28 (1.60–6.74)0.0012.45 (1.16–5.15)0.0182 yearsLOY < 18%43 (5.1)1 (Ref)1 (Ref)1 (Ref)LOY ≥ 18%13 (14.1)2.88 (1.55–5.36)0.0012.96 (1.59–5.52)0.0012.11 (1.11–4.01)0.0243 yearsLOY < 18%53 (6.3)1 (Ref)1 (Ref)1 (Ref)LOY ≥ 18%14 (15.2)2.53 (1.41–4.57)0.0022.56 (1.41–4.62)0.0021.88 (1.02–3.45)0.043CI confidence interval, HR hazard ratio, Ref reference.Model 1: adjusted for body mass index, current smoker, hypertension, dyslipidemia, diabetes mellitus, and peripheral artery disease.Model 2: model 1+ age. Adjusted survival curves derived from multivariable Cox models for the cumulative survival rate between groups by dichotomized loss of Y chromosome ratio. A The entire follow-up period; B 1 year; C 2 years; D 3 years. The cutoff value for LOY was 18% (top 10% percentile). Follow-up time was initiated on the day of the percutaneous coronary intervention. The multivariable Cox model was adjusted for age, body mass index, current smoker, hypertension, dyslipidemia, diabetes mellitus, and peripheral artery disease (Model 2). LOY loss of Y chromosome. Table 2Association between all-cause death and dichotomized loss of Y chromosome ratioFollow-up timeGroupEvent(n.%)crude.HR (95% CI)P-valueModel 1HR (95% CI)P-valueModel 2HR (95% CI)P-valueAllLOY < 18%78 (9.3)1 (Ref)1 (Ref)1 (Ref)LOY ≥ 18%15 (16.3)2.00 (1.15–3.48)0.0142.01 (1.15–3.50)0.0141.30 (0.74–2.29)0.3681 yearLOY < 18%29 (3.5)1 (Ref)1 (Ref)1 (Ref)LOY ≥ 18%10 (10.9)3.24 (1.58–6.64)0.0013.28 (1.60–6.74)0.0012.45 (1.16–5.15)0.0182 yearsLOY < 18%43 (5.1)1 (Ref)1 (Ref)1 (Ref)LOY ≥ 18%13 (14.1)2.88 (1.55–5.36)0.0012.96 (1.59–5.52)0.0012.11 (1.11–4.01)0.0243 yearsLOY < 18%53 (6.3)1 (Ref)1 (Ref)1 (Ref)LOY ≥ 18%14 (15.2)2.53 (1.41–4.57)0.0022.56 (1.41–4.62)0.0021.88 (1.02–3.45)0.043CI confidence interval, HR hazard ratio, Ref reference.Model 1: adjusted for body mass index, current smoker, hypertension, dyslipidemia, diabetes mellitus, and peripheral artery disease.Model 2: model 1+ age. Association between all-cause death and dichotomized loss of Y chromosome ratio CI confidence interval, HR hazard ratio, Ref reference. Model 1: adjusted for body mass index, current smoker, hypertension, dyslipidemia, diabetes mellitus, and peripheral artery disease. Model 2: model 1+ age. Regarding the association between LOY and all-cause mortality within 1 year of follow-up, the unadjusted Kaplan–Meier curve indicated that the 1-year all-cause mortality rate was higher in males with LOY ≥ 18% compared to those with LOY < 18% (Plog-rank < 0.001, Fig. S4B). Univariable Cox analysis demonstrated that patients with LOY ≥ 18% had a 3.24-fold higher risk of all-cause mortality than those with LOY < 18% (95% CI: 1.58–6.64; P = 0.001, Table 2). The risk still increased to 3.28 times even after adjusting for traditional cardiovascular risk factors except for age (Model 1: 95% CI: 1.60–6.74; P = 0.001, Table 2), whereas decreased to 2.45 times after adjusting for confounders including age (Model 2: 95% CI: 1.16–5.15; P = 0.018, Table 2 and Fig. 1B). Furthermore, extended Cox regression analyses showed that the mortality risk in patients with LOY ≥ 18% remained significantly higher than those with LOY < 18% (Model 3: HR 2.24, 95% CI: 1.06–4.70; P = 0.034, Model 4: HR 2.26, 95% CI: 1.07–4.76; P = 0.032, Table S5). Besides, RCS regression analysis suggested an increasing trend in the risk of 1-year all-cause mortality with increasing LOY; however, this did not reach statistical significance (Pfor linearity = 0.162, Pfor nonlinearity = 0.528, Fig. S5B). Regarding the relationship between LOY and all-cause mortality within 2 and 3 years of follow-up, unadjusted Kaplan–Meier curves, Cox regression, adjusted survival curves derived from Cox models and RCS showed similar results (Fig. S4C, D, Tables 2, S5, Figs. 1C, D, and S5C, D). In summary, male patients with LOY ≥ 18% were at a substantially higher risk of all-cause mortality compared to those with LOY < 18%. Specifically, the risk of all-cause mortality within 1 year was significantly higher, regardless of traditional cardiovascular risk factors. The effect of age on the association between LOY and all-cause mortality Given the positive association between LOY and age, subgroup analyses stratified by 10-year age intervals were performed, with the cutoff for high LOY defined as the top 10% within each age group. Among patients aged 41–50 years, Kaplan–Meier analysis demonstrated a significant difference in all-cause mortality between the high and low LOY groups (Plog-rank = 0.050, Fig. S7B). Although the univariable Cox regression analysis indicated a slightly higher mortality risk in the high LOY group, this association did not achieve statistical significance (HR 4.66, 95% CI: 0.85–25.50; P = 0.076, Fig. S7B). Similar results were observed in patients aged 51–60 years (Fig. S7C). In contrast, no statistically significant associations were observed in the other age groups (Fig. S7). Overall, there was a trend toward an increased risk of all-cause mortality among patients with high LOY in the 40–60-year age range; however, this trend did not reach statistical significance. The effect of previous MI on the association between LOY and all-cause mortality The subgroup analysis results suggested an interaction between previous MI and the reduced survival associated with LOY (Pfor interaction = 0.011; Fig. S6). The all-cause mortality was higher in males with previous MI than in those without previous MI (17.3% [27/156] vs. 8.5% [66/772]). Further analyses showed that among males without prior MI, those with LOY ≥ 18% had a significantly higher risk of all-cause mortality compared with those with LOY < 18%, and this association remained significant after multivariable adjustment, including age (Model 2: HR 1.93, 95% CI: 1.01–3.67; P = 0.045; Fig. S8A and Table S6). In addition, the risk of 1-year all-cause mortality was significantly higher in males with LOY ≥ 18% than in those with LOY < 18% after adjustment, including age (Model 2: HR 3.80, 95% CI: 1.63–8.86; P = 0.002; Table S6). Similar significant associations were observed for 2-year and 3-year mortality (Table S6). In contrast, no significant associations were observed among males with prior MI (Fig. S8B and Table S6). All-cause mortality in male patients stratified into high and low LOY groups and female patients Analyses including female participants are exploratory and descriptive, not mechanistic, due to their limited biological interpretability. A total of 272 female patients undergoing emergency PCI for STEMI were included. The incidence of all-cause mortality in females was 16.5% (45/272), higher than in all male patients (10.0%), but similar to males with LOY ≥ 18% (16.3%). The Kaplan–Meier curves in Fig. S9 demonstrated significant differences in the overall, 2-, and 3-year all-cause mortality between male and female patients (all Plog-rank < 0.05). Consistently, univariable Cox regression showed that female patients had a higher risk of all-cause mortality than male patients over the entire follow-up period and at the 2-year and 3-year time points (Table S7). However, after multivariable adjustment, the association between sex and all-cause mortality was no longer statistically significant over the entire follow-up period or at the 2-year and 3-year intervals (Model 2, Table S7). The unadjusted Kaplan–Meier curves in Fig. S10 demonstrated significant differences in the all-cause mortality rates among the three groups during the overall, 1-, 2-, and 3-year follow-up (all P log-rank < 0.001). Pairwise comparisons showed that compared to male patients with LOY < 18%, female patients had increased all-cause mortality rates at all analysed times (all Plog-rank < 0.05, data not shown). However, no statistically significant differences between female patients and male patients with LOY ≥ 18% were observed (all Plog-rank > 0.05, data not shown). Univariable Cox analysis indicated that female patients showed an elevated risk of mortality compared to male patients with LOY < 18% (crude HR 1.89, 95% CI: 1.31–2.72; P = 0.001, Table S7), even after adjusting for traditional cardiovascular risk factors excluding age (Model 1: HR 1.71, 95% CI: 1.04–2.81; P = 0.035, Table S7); however, the difference disappeared after adjusting for all confounding factors (Model 2: HR 1.06, 95% CI: 0.66–1.70; P = 0.818, Table S7 and Fig. S11A). Similarly, female patients faced a higher risk of all-cause mortality at 1 year and 3 years than male patients with LOY < 18% in the crude model and Model 1, whereas the differences became nonsignificant in Model 2 (Table S7 and Fig. 11B, D). Discussion This study investigated the association between LOY and all-cause mortality among patients with STEMI who underwent emergency PCI. In this study, we demonstrated that a high level of LOY (≥18%) was associated with an increased risk of all-cause mortality in male patients with STEMI, particularly during short- and mid-term follow-up (1–3 years). This association remained significant after adjustment for traditional cardiovascular risk factors, including age. Subgroup analyses suggested that the association might be more evident in males without a prior MI, and this finding should be interpreted with caution. Together, these findings suggest that LOY may represent a genomic marker of mortality risk in patients with STEMI. Existing studies indicate that LOY is associated with reduced survival and shortened lifespan in males. Forsberg et al. analysed peripheral blood from 1153 elderly men and found that LOY ≥ 35% in the peripheral blood cells suggested an elevated risk of all-cause mortality (HR 1.91, 95% CI: 1.17–3.13; P = 0.010). The median survival time for individuals with LOY ≥ 35% was 5.5 years shorter than that of the control group8. A study by Mas-Peiro et al. focused on elderly men after successful transcatheter aortic valve replacement and indicated that LOY > 17% was an independent predictor for death (adjusted HR 2.08, 95% CI 1.36–3.17; P = 0.001)19. Sano et al. showed that males with LOY > 40% in leukocytes displayed a 31% increased risk of circulatory system disease-associated mortality (HR 1.31, 95% CI 1.02–1.70; P = 0.038)13. Haitjema et al. enrolled males who underwent carotid endarterectomy and reported that LOY was linked to an elevated risk of a composite endpoint of cardiovascular death, stroke, MI, fatal heart failure, and fatal aneurysm rupture (HR 2.28, 95% CI 1.11–4.67; P = 0.020)11. Consistent with previous studies, our results indicate that LOY is associated with an increased risk of all-cause mortality in male patients with STEMI. Aged-adjusted multivariable Cox regression showed that males with LOY ≥ 18% had approximately twofold higher risks of mortality at 1-year, 2-year, and 3-year follow-up compared with those with LOY < 18% (Model 2: 1 year: HR 2.45, 95% CI: 1.16–5.15, P = 0.018; 2 years: HR 2.11, 95% CI: 1.11–4.01, P = 0.024; 3 years: HR 1.88, 95% CI: 1.02–3.45, P = 0.043; Table 2). These findings suggest that LOY may have potential clinical value as a biomarker for prognosis prediction in male patients with STEMI. However, the substantial increase in censoring after approximately 1000 days of follow-up, driven by staggered cohort entry and the fixed end of observation, likely reduced the statistical power to detect long-term between-group differences and may have contributed to the attenuation and loss of significance of the adjusted HR for the entire follow-up period. In comparison, earlier follow-up intervals, such as 1-, 2-, and 3-year intervals, where event density was higher, and censoring was less pronounced, may provide more reliable estimates of the association between LOY and mortality. Given the known positive association between age and LOY4, two multivariable-adjusted models were constructed: Model 1 excluded age, whereas Model 2 additionally included age. As shown in Table 2, further adjustment for age attenuated the observed associations. The HR for all-cause mortality over the entire follow-up period did not reach statistical significance, which may be influenced by a substantial increase in censoring after approximately 1000 days of follow-up. The HRs for all-cause mortality at 1-year, 2-year, and 3-year follow-up remained directionally consistent, though decreased by 25%, 29%, and 27%, respectively. These findings indicate that the association between LOY and mortality is partially influenced by age and should therefore be interpreted with caution in terms of causal inference. In addition, we explored the association between LOY and all-cause mortality across age subgroups stratified by 10-year intervals. A trend toward an increased risk of all-cause mortality associated with high LOY was observed only among patients aged 40–60 years (Fig. S7). However, the sample sizes within each age subgroup were relatively limited, which may have reduced the statistical power to detect significant associations. Future studies with larger sample sizes are therefore warranted to validate these findings. Nevertheless, these results suggest that age-specific thresholds of LOY may merit consideration when evaluating its potential clinical utility for risk stratification. Furthermore, subgroup analysis indicated that among patients without previous MI, those with LOY ≥ 18% had a 1.93-fold higher risk of all-cause mortality than those with LOY < 18% (Model 2: adjusted HR 1.93, 95% CI: 1.01–3.67; P = 0.045, Fig. S8 and Table S6), whereas no similar results have been observed in patients with prior MI. Previous studies have indicated that the proportion of LOY in some males remains stable or decreases with age, possibly due to interactions between genetic background and environmental factors20. It is conceivable that a major cardiovascular event, such as MI, may further modify the dynamics of LOY, thereby complicating its relationship with long-term prognosis. Notably, the number of patients with prior MI in the present study was relatively limited (n = 156), which may have reduced the statistical power to detect significant associations in this subgroup. In addition, these analyses were exploratory, and no adjustment for multiple testing was applied; therefore, subgroup-specific and causal inferences should be interpreted with caution. Overall, while LOY may have potential value in prognostic assessment and risk stratification, particularly in patients without prior MI, larger studies with repeated measurements of LOY are warranted to further clarify its prognostic significance. Sex differences in the prognosis of patients with STEMI have been extensively investigated. Previous studies have generally reported higher mortality rates among female patients compared with male patients. This observed disparity has been attributed to differences in baseline cardiovascular risk profiles and clinical characteristics, as well as to delays in hospital presentation and diagnosis, and a lower likelihood of receiving evidence-based therapies, including beta-blockers and timely reperfusion, among women22. However, several studies have shown that this sex-related difference in mortality becomes nonsignificant after adjustment for baseline characteristics14,23,24. Consistent with these findings, the present study demonstrated that the association between sex and all-cause mortality was no longer statistically significant after full adjustment for traditional cardiovascular risk factors, including age. Additionally, in Cox regression analyses adjusted for traditional cardiovascular risk factors excluding age (Model 1), female patients had higher all-cause mortality compared with males with LOY < 18%, with HRs of 1.71 (overall), 2.41 (1-year), and 2.06 (3-year) (all P < 0.05; Table S7), corresponding to 71%, 141%, and 106% higher risk, respectively. These differences were substantially attenuated after further adjustment for age (Model 2, Table S7). Moreover, no significant differences in all-cause mortality were observed between females and males with LOY ≥ 18% (Table S7). These findings highlight three key considerations. First, age is a major determinant of post-STEMI prognosis and is strongly associated with both LOY prevalence and mortality; failing to adjust for age can lead to overestimation of crude HRs, as reflected by the attenuation from Model 1 to Model 2. Second, the relatively small number of female patients limited statistical power and resulted in wide confidence intervals, reducing the ability to detect modest sex-specific effects. Third, the inclusion of female patients as a reference group has inherent biological limitations. Given fundamental differences in karyotype (constitutional XX vs. mosaic LOY), X chromosome dosage, and hormonal milieu, these comparisons are not mechanistically equivalent and should be interpreted with caution. Such analyses are therefore exploratory and primarily descriptive in nature, not mechanistic. Overall, while these data do not demonstrate a robust difference in mortality between female patients and males with high or low LOY, they suggest that LOY detection may provide additional insight into sex-specific prognostic patterns and could help identify male patients with a relatively favorable prognosis after STEMI. Aging, genetic variation, Y chromosome structural aberrations, and smoking are risk factors for LOY, and they may have cumulative effects6,7,25–27. However, the potential mechanisms underlying the adverse prognosis of cardiovascular diseases caused by LOY remain unclear. One possible explanation for this is that LOY serves as a biomarker of genomic instability, affecting individual susceptibility to systemic diseases. Research suggests that genetic variants associated with LOY risk involve genes related to cell proliferation, cell cycle regulation, DNA damage response, and apoptosis, which overlap with cancer susceptibility and may contribute to an increase in all-cause mortality5,28. Additionally, LOY risk variants are also associated with susceptibility to other age-related diseases. For instance, KCNQ1 variants in East Asian and European populations are closely associated with the susceptibility to type 2 diabetes5,29,30. Another possible explanation is that blood cells with LOY behave differently from normal blood cells, directly affecting the tissues in which they infiltrate. Animal studies have shown that mice deficient in the Y chromosome in blood cells are prone to cardiac fibrosis during the unprovoked aging process13. Single-cell RNA sequencing and immunohistochemical analysis have revealed that recruited LOY macrophages in the heart exhibit abnormal necrotic differentiation and produce more necrotic molecules, such as transforming growth factor-β1 (TGF-β1)13. A study by Mas-Peiro et al. demonstrated that LOY monocytes exhibited increased sensitivity to pro-fibrotic signals19. In summary, the heightened sensitivity of LOY monocytes to the TGF-β signaling pathway may lead to their recruitment to cardiac tissue and promote cardiac fibrosis, thereby resulting in an adverse prognosis and disease progression. A major strength of this study is its use of a real-world cohort of male patients with STEMI, which highlights the clinical significance of LOY and provides valuable information for risk stratification in this population. However, several limitations should be noted. First, while multivariable Cox regression suggested that LOY is an independent predictor of mortality beyond traditional cardiovascular risk factors, this finding alone does not establish causality. In addition, the inconsistency observed over the entire follow-up period may be influenced by increased censoring and a reduced number of participants at risk in later follow-up, which could affect the stability and precision of the estimates. Second, this was a moderately sized, single-center study; analyses of subgroups stratified by 10-year intervals and previous MI may have been underpowered due to relatively small numbers in each subgroup. Third, the female cohort was substantially smaller than the male cohort, limiting the ability to detect modest sex-specific differences; exploratory comparisons involving female patients are limited by fundamental biological differences in karyotype, X chromosome dosage, and hormonal milieu, and therefore should not be interpreted as mechanistic analogs of LOY. Fourth, LOY levels were measured only at baseline, and repeated measurements during follow-up could provide additional prognostic information. Finally, information on hematologic and active solid malignancies was not systematically available for this cohort, which may influence both LOY and survival; residual confounding cannot be excluded. Taken together, these limitations should be considered when interpreting the results, and future studies with larger sample sizes and longitudinal LOY assessments are warranted to further clarify the role of age and LOY in post-STEMI prognosis. Conclusion In male STEMI patients, LOY (≥18%) was associated with an increased risk of all-cause mortality during short- and intermediate-term follow-up, with exploratory analyses suggesting a stronger effect in those without prior MI. These findings support LOY as a potential genomic biomarker for risk stratification, and further studies with larger, longitudinal cohorts are warranted to validate its clinical utility. Supplementary information COMMSMED-25-1569-s01 COMMSMED-25-1569-s02 COMMSMED-25-1569-s01 COMMSMED-25-1569-s02